|By PR Newswire||
|August 11, 2014 09:20 AM EDT||
NEW YORK, August 11, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Covidien plc (NYSE: COV), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5626-100free.
Medtronic, Inc. Research Reports
On August 1, 2014, Medtronic, Inc. (Medtronic) launched NuVent(TM) EM Sinus Dilation System for the Fusion® ENT Navigation System, developed and manufactured by the Company's Ear Nose and Throat (ENT) division of its Surgical Technologies business. Medtronic informed that NuVent is the first and only balloon sinus dilation system with built-in electromagnetic (EM) surgical navigation technology to help the surgeon confirm anatomy and optimize balloon placement during balloon sinus surgery. Further, the NuVent integrates technology with "plug and play" simplicity through which surgeons can see the precise location of the NuVent instrument's tip on the Fusion screen. Vince Racano, Vice President and General Manager, ENT division, Medtronic, said, "This system is another example of our innovative integration of technologies and therapies that brings Medtronic Surgical Synergy(TM) to the operating room, driving procedural excellence, economic value, and patient care." The full research reports on Medtronic are available to download free of charge at:
Covidien plc Research Reports
On August 6, 2014, Covidien plc's (Covidien) stock declined 2.07% to end the trading session at $84.77, underperforming the Dow Jones Industrial Average (DJIA) that moved up 0.08% over the same trading session. Covidien's stock opened the session at $84.00 and oscillated in the range of $82.38 - $85.06. A total of 13.17 million shares were traded during the day, which is above its 30-day average volume of 5.28 million. Over the past three months, the stock has returned 19.18%, outperforming the DJIA that lost 0.26% over the same period. The full research reports on Covidien are available to download free of charge at:
Johnson & Johnson Research Reports
On July 28, 2014, Johnson & Johnson (Johnson & Johnson) reported that the results of the Phase 2 COSMOS (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) clinical study, published on July 28, 2014 in The Lancet, demonstrated that 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with Janssen R&D Ireland's (Janssen) simeprevir, an NS3/4A protease inhibitor, in combination with sofosbuvir, achieved sustained virologic response 12 weeks after the end of treatment (SVR12), including those patients with compensated cirrhosis and prior null response to treatment with pegylated interferon (PegIFN) and ribavirin (RBV). The Company stated that the open-label, randomised Phase 2 COSMOS study investigated the efficacy and safety of 12 or 24 weeks of simeprevir (150 mg once daily) with sofosbuvir (400 mg once daily) without or with RBV in HCV genotype 1 chronically infected patients with compensated liver disease. The full research reports on Johnson & Johnson are available to download free of charge at:
Merck & Co., Inc. Research Reports
On August 5, 2014, Merck & Co., Inc. (Merck) announced that it has successfully completed the tender offer to acquire all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (Idenix) at a purchase price of $24.50 per share. Merck informed that as on August 4, 2014, 131.7 million shares of Idenix's common stock were validly tendered and not withdrawn from the offer, representing c.82.5% of the total outstanding common stock of Idenix on a fully diluted basis. Post the completion of tender offer, the Company plans to complete the acquisition of Idenix through a merger of Merck's wholly-owned subsidiary with and into Idenix without stockholder approval. After the completion of merger, Idenix will become a wholly-owned subsidiary of Merck and shares of Idenix will cease to trade on NASDAQ Stock Market. The full research reports on Merck are available to download free of charge at:
Jazz Pharmaceuticals plc Research Reports
On August 5, 2014, Jazz Pharmaceuticals plc (Jazz) reported Q2 2014 total revenues of $291.2 million, up 39.8% YoY, driven primarily by net product sales of Xyrem® (sodium oxybate) oral solution, Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi) and defibrotide, marketed under the name Defitelio® (defibrotide) in Europe. The Company's Q2 2014 net income attributable to Jazz came in at $43.7 million or $0.70 per diluted share, compared to $42.2 million or $0.69 per diluted share in Q2 2013. The Company reported 33.0% YoY growth in its H1 2014 total revenues to $538.1 million, while the net loss attributable to Jazz came in at $49.0 million, compared to net income of $85.6 million in H1 2013. For full-year 2014, the Company expects revenues between $1.1 and $1.2 billion; net product sales between $1.1 and $1.2 billion; and diluted EPS in the range of $0.47 - $0.90. The full research reports on Jazz are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review